Trade Mark Journal No.2026/031 31 July 2026

UK00004394786 29 May 2026 (5,42)

ATRIUM

International priority date claimed: 11 December 2025 (United States of America) (99543378)

Class 5: Biological, medicinal and pharmaceutical preparations, namely, oligonucleotide-based therapeutics for the treatment of cardiovascular, cardiomyopathies, and heart muscle related diseases and disorders.
Class 42: Providing medical and scientific research information in the fields of pharmaceuticals and biotechnology.

Atrium Therapeutics, Inc.

Representative: Abion UK Limited